10 Stocks Under $10 that Will Triple

4. Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Upside Potential: 319.03%

Number Of Hedge Funds: 36

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) develops targeted therapies for pediatric and adult diseases. The company works along multiple clinical-stage operations with its main product, an oral treatment for children with relapsed or refractory brain tumors. In addition, it is also advancing other drugs for various cancers in both age groups, which are still in the early testing phases.

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) posted a net product revenue of $29 million in Q4 2024, with yearly sales hitting $57.2 million. The quarterly sales jumped 44% from the previous quarter, fueled by strong prescription growth after the product’s launch in April 2024. The company also earned $73.9 million in license revenue by selling commercial rights outside America. While operating costs increased, R&D expenses reached $227.7 million in 2024 due to milestone payments and ongoing studies. Despite these expenditures, Day One has a strong cash position at the end of 2024, with $531.7 million in cash.

In its clinical pipeline, Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) pushed forward with its Phase 3 trial for pediatric patients with expectations to finish enrollment by early 2026. Moreover, the company’s early-stage cancer drug completed initial dose testing. In addition, a new designation from the Centers for Medicare & Medicaid Services reduced its rebate obligations, boosting the company’s finances.

As such, Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) is catching the attention of analysts and hedge funds, thanks to its growing sales and expanding pipeline. While rising prescriptions and late-stage progress strengthen its upside potential, the solid cash position allows it to rank among stocks under $10 that will triple.